Soleno Therapeutics (SLNO) said late Tuesday it has signed an up to $200 million loan and security agreement with Oxford Finance.
Soleno said it drew $50 million at closing, and $100 million will be available in three additional tranches, subject to US Food and Drug Administration approval of diazoxide choline extended-release tablets to treat Prader-Willi syndrome as well as commercial milestones.
The company said a final $50 million tranche may be made available upon the mutual consent of Soleno and Oxford.
Soleno said that, with the initial $50 million draw, it had pro-forma cash, cash equivalents and marketable securities of $334.7 million as of Sept. 30.
Shares of the company fell 3.5% in recent after-hours activity.
Price: 46.00, Change: -1.65, Percent Change: -3.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.